Sona Nanotech Inc. (SNANF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.58 Million CAD | 54.21% |
| 2022 | 1.02 Million CAD | -62.55% |
| 2021 | 2.74 Million CAD | -33.98% |
| 2020 | 4.16 Million CAD | 121.09% |
| 2019 | 1.88 Million CAD | -36.83% |
| 2018 | 2.97 Million CAD | 74.09% |
| 2017 | 1.71 Million CAD | -21.3% |
| 2016 | 2.17 Million CAD | -36.94% |
| 2015 | 3.44 Million CAD | 31.29% |
| 2014 | 2.62 Million CAD | 38.98% |
| 2013 | 1.88 Million CAD | 114.19% |
| 2012 | 882.12 Thousand CAD | -39.19% |
| 2011 | 1.45 Million CAD | 64.39% |
| 2010 | 882.43 Thousand CAD | 26.37% |
| 2009 | 698.27 Thousand CAD | -49.94% |
| 2008 | 1.39 Million CAD | 94.08% |
| 2007 | 718.65 Thousand CAD | 147.69% |
| 2006 | 290.14 Thousand CAD | 7525.36% |
| 2005 | 3805.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.12 Million CAD | 21.72% |
| 2024 Q1 | 1.33 Million CAD | -15.68% |
| 2024 Q2 | 1.74 Million CAD | 30.23% |
| 2023 FY | 1.58 Million CAD | 54.21% |
| 2023 Q2 | 1.16 Million CAD | 3.45% |
| 2023 Q4 | 1.58 Million CAD | 12.83% |
| 2023 Q1 | 1.12 Million CAD | 9.4% |
| 2023 Q3 | 1.4 Million CAD | 20.76% |
| 2022 Q2 | 1.34 Million CAD | 4.14% |
| 2022 Q3 | 1.15 Million CAD | -14.2% |
| 2022 Q4 | 1.02 Million CAD | -10.77% |
| 2022 FY | 1.02 Million CAD | -62.55% |
| 2022 Q1 | 1.29 Million CAD | -53.03% |
| 2021 Q1 | 3.82 Million CAD | -8.08% |
| 2021 Q3 | 3.35 Million CAD | -16.74% |
| 2021 FY | 2.74 Million CAD | -33.98% |
| 2021 Q4 | 2.74 Million CAD | -18.16% |
| 2021 Q2 | 4.03 Million CAD | 5.41% |
| 2020 Q3 | 3.85 Million CAD | 21.81% |
| 2020 Q1 | 1.35 Million CAD | -28.07% |
| 2020 FY | 4.16 Million CAD | 121.09% |
| 2020 Q4 | 4.16 Million CAD | 7.78% |
| 2020 Q2 | 3.16 Million CAD | 134.13% |
| 2019 Q2 | 2.98 Million CAD | 2.83% |
| 2019 FY | 1.88 Million CAD | -36.83% |
| 2019 Q1 | 2.9 Million CAD | -2.56% |
| 2019 Q4 | 1.88 Million CAD | -13.37% |
| 2019 Q3 | 2.17 Million CAD | -27.22% |
| 2018 Q3 | 1.96 Million CAD | 7.23% |
| 2018 Q1 | 29.22 Million CAD | 1607.88% |
| 2018 FY | 2.97 Million CAD | 74.09% |
| 2018 Q4 | 2.97 Million CAD | 51.65% |
| 2018 Q2 | 1.83 Million CAD | -93.73% |
| 2017 Q3 | 2.01 Million CAD | -1.4% |
| 2017 Q2 | 2.04 Million CAD | -0.18% |
| 2017 Q1 | 2.04 Million CAD | -5.72% |
| 2017 FY | 1.71 Million CAD | -21.3% |
| 2017 Q4 | 1.71 Million CAD | -15.18% |
| 2016 Q4 | 2.17 Million CAD | -6.27% |
| 2016 FY | 2.17 Million CAD | -36.94% |
| 2016 Q3 | 2.31 Million CAD | 0.14% |
| 2016 Q2 | 2.31 Million CAD | -36.92% |
| 2016 Q1 | 3.67 Million CAD | 6.5% |
| 2015 Q3 | 3.32 Million CAD | 12.19% |
| 2015 Q4 | 3.44 Million CAD | 3.78% |
| 2015 Q2 | 2.96 Million CAD | 14.42% |
| 2015 Q1 | 2.58 Million CAD | -1.45% |
| 2015 FY | 3.44 Million CAD | 31.29% |
| 2014 FY | 2.62 Million CAD | 38.98% |
| 2014 Q2 | 1.86 Million CAD | -4.18% |
| 2014 Q3 | 2.53 Million CAD | 36.05% |
| 2014 Q4 | 2.62 Million CAD | 3.6% |
| 2014 Q1 | 1.94 Million CAD | 2.91% |
| 2013 Q4 | 1.88 Million CAD | 162.86% |
| 2013 Q1 | 788.07 Thousand CAD | -10.66% |
| 2013 Q2 | 725.07 Thousand CAD | -8.0% |
| 2013 Q3 | 718.81 Thousand CAD | -0.86% |
| 2013 FY | 1.88 Million CAD | 114.19% |
| 2012 FY | 882.12 Thousand CAD | -39.19% |
| 2012 Q1 | 828.31 Thousand CAD | -42.9% |
| 2012 Q2 | 1.11 Million CAD | 34.14% |
| 2012 Q3 | 857.95 Thousand CAD | -22.79% |
| 2012 Q4 | 882.12 Thousand CAD | 2.82% |
| 2011 FY | 1.45 Million CAD | 64.39% |
| 2011 Q2 | 779.04 Thousand CAD | -28.98% |
| 2011 Q1 | 1.09 Million CAD | 24.31% |
| 2011 Q4 | 1.45 Million CAD | 52.66% |
| 2011 Q3 | 950.23 Thousand CAD | 21.97% |
| 2010 FY | 882.43 Thousand CAD | 26.37% |
| 2010 Q4 | 882.43 Thousand CAD | 61.01% |
| 2010 Q1 | 651.83 Thousand CAD | -6.65% |
| 2010 Q3 | 548.05 Thousand CAD | -3.86% |
| 2010 Q2 | 570.07 Thousand CAD | -12.54% |
| 2009 Q3 | 750.1 Thousand CAD | 0.37% |
| 2009 FY | 698.27 Thousand CAD | -49.94% |
| 2009 Q4 | 698.27 Thousand CAD | -6.91% |
| 2009 Q1 | 1.24 Million CAD | -10.46% |
| 2009 Q2 | 747.37 Thousand CAD | -40.15% |
| 2008 FY | 1.39 Million CAD | 94.08% |
| 2008 Q4 | 1.39 Million CAD | 105.71% |
| 2008 Q1 | 628.08 Thousand CAD | -12.6% |
| 2008 Q3 | 678.03 Thousand CAD | 23.72% |
| 2008 Q2 | 548.03 Thousand CAD | -12.74% |
| 2007 Q4 | 718.65 Thousand CAD | 67.63% |
| 2007 FY | 718.65 Thousand CAD | 147.69% |
| 2007 Q2 | 715.73 Thousand CAD | 289.84% |
| 2007 Q1 | 183.59 Thousand CAD | -36.72% |
| 2007 Q3 | 428.71 Thousand CAD | -40.1% |
| 2006 Q4 | 290.14 Thousand CAD | -48.47% |
| 2006 Q3 | 563.07 Thousand CAD | 45.64% |
| 2006 FY | 290.14 Thousand CAD | 7525.36% |
| 2006 Q1 | 3805.00 CAD | 0.0% |
| 2006 Q2 | 386.61 Thousand CAD | 10060.63% |
| 2005 FY | 3805.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 56.034% |
| Arrayit Corporation | 7.49 Million USD | 78.84% |
| Atlantic International Corp. | 3.82 Million USD | 58.568% |
| Biocept, Inc. | 22.01 Million USD | 92.794% |
| Bioqual, Inc. | 18.93 Million USD | 91.624% |
| CardioGenics Holdings Inc | 1.79 Million USD | 11.624% |
| DermTech, Inc. | 64.75 Million USD | 97.55% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.784% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 87.193% |
| iMD Companies, Inc. | 1.67 Million USD | 5.252% |
| IDenta Corp. | 1.01 Million USD | -56.568% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 94.366% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -432.404% |
| InVitro International | 78.99 Thousand USD | -1908.207% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 91.96% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -1126.852% |
| Medical Imaging Corp. | 9.51 Million USD | 83.332% |
| NovelStem International Corp. | 4.2 Million USD | 62.286% |
| Optigenex Inc. | 9.57 Million USD | 83.425% |
| PharmChem, Inc. | 558.64 Thousand USD | -183.951% |
| Proteome Sciences plc | 18.48 Million USD | 91.42% |
| Response Genetics, Inc | 15.86 Million USD | 90.003% |
| Rennova Health, Inc. | 49.66 Million USD | 96.806% |
| RushNet, Inc. | 6.23 Million USD | 74.575% |
| ScreenPro Security Inc. | 1.6 Million USD | 0.894% |
| Stella Diagnostics Inc. | 18 Million USD | 91.19% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 80.664% |
| Todos Medical Ltd. | 50.15 Million USD | 96.837% |